43 filings
Page 2 of 3
6-K
dkzfrszs 45qt
30 Aug 22
Current report (foreign)
4:01pm
6-K
qki7dcxdxokbwc okkbf
19 Aug 22
Current report (foreign)
6:06am
6-K
b05mnpy987tu0d36sy
11 Jul 22
Current report (foreign)
4:30pm
6-K
7ugd3v x75t7frh
17 Jun 22
Current report (foreign)
4:06pm
6-K
i6n ll5fjpvv
10 Jun 22
Current report (foreign)
6:05am
6-K
icjfq t1iv1vtf0xcfhm
9 May 22
Current report (foreign)
4:10pm
6-K
0fev gxsn2
5 May 22
Current report (foreign)
6:04am
6-K
sf1dpjsv7z2zjgycofb
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
oauk 0c3o
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
6-K
rqef1nb79
1 Mar 22
Current report (foreign)
4:16pm
6-K
s2n 3kmnhyweuzy
16 Feb 22
Current report (foreign)
4:01pm
6-K
b3zl2o5i3d3gzjz5
5 Jan 22
Current report (foreign)
5:24pm
6-K
lzmu2n ea2jjbun
22 Nov 21
Current report (foreign)
5:12pm
6-K
xzkwq
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
nbdlywcy j0h
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
p7byqs
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
8uvvsci3kblhl5
2 Sep 21
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial
4:40pm
6-K
fkhjk
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
0bdy1w
27 Aug 21
Current report (foreign)
4:10pm
6-K
39zqgb73
16 Jun 21
Current report (foreign)
4:01pm